BRIEF-Revance Therapeutics plans to initiate global phase 3 program in second half of 2016
July 14 (Reuters) - Revance Therapeutics Inc :
* Revance Announces Completion Of Pre-Phase 3 meeting with FDA for rt002 injectable to treat glabellar lines
* Company plans to initiate global phase 3 program in second half of 2016
* Co's phase 3 program will include two placebo-controlled pivotal studies conducted at multiple sites in US and Canada Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.